Frontiers in Drug Delivery is a multidisciplinary, DOAJ-indexed journal that focuses on drug delivery concepts at a cell and tissue level, through to translational outcomes in preclinical and clinical studies for drug formulations and formulations combined with devices.

The journal is led by Field Chief Editor Prof David Brayden (University College Dublin, Ireland) and welcomes submissions in all areas of drug delivery research focusing on key delivery routes as well as on important specific disease or product areas where delivery can play an important role.

The following subject areas are covered:

CNS drug delivery
cardiovascular drug delivery
dermatological drug delivery
drug delivery for special patient populations
hepatic drug delivery
ophthalmic drug delivery
oral drug delivery
respiratory drug delivery
technological and methodological advances in drug delivery
vaccine delivery.

Submissions from the following research areas are also encouraged:

artificial intelligence research for drug release and feedback systems
computational design of formulation components
3D printing of tablets and implants
advanced in silico and in vitro assays of performance of the delivered drug in the body
toxicology aspects of drug delivery systems.

In particular, the journal welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being.

Manuscripts purely relating to drug discovery that is not associated with delivery aspects are not suitable for publication in this journal.

Frontiers in Drug Delivery is committed to advancing developments in the field of drug delivery by communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.

Impact

Frontiers in Drug Delivery

Technological and Methodological Advances in Drug Delivery